Literature DB >> 9602362

Analysis of the targeting of the hypermutational machinery and the impact of subsequent selection on the distribution of nucleotide changes in human VHDJH rearrangements.

T Dörner1, S J Foster, H P Brezinschek, P E Lipsky.   

Abstract

B cells are unique in that they generate and tolerate a high rate of mutations in their antigen receptor genes and employ these mutations as a basis of avidity maturation. The precise role of the mutational machinery versus subsequent selection in determining the frequency and distribution of mutations has not been fully analyzed. To address these issues, the influence of the intrinsic mutational machinery and subsequent selection on the frequency and distribution of mutations in the expressed human immunoglobulin repertoire was analyzed. Analysis of non-productively rearranged VH genes from individual human B cells provided an opportunity to examine the immediate impact of somatic hypermutation without superimposed selective influences. Comparison with the frequency and distribution of mutations in the productively rearranged human VH genes permitted an estimate of the influences of subsequent selection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9602362     DOI: 10.1111/j.1600-065x.1998.tb01439.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  19 in total

1.  Expression of error-prone polymerases in BL2 cells activated for Ig somatic hypermutation.

Authors:  V Poltoratsky; C J Woo; B Tippin; A Martin; M F Goodman; M D Scharff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

2.  Sequence similarities of protein kinase peptide substrates and inhibitors: comparison of their primary structures with immunoglobulin repeats.

Authors:  J Kubrycht; J Borecký; K Sigler
Journal:  Folia Microbiol (Praha)       Date:  2002       Impact factor: 2.099

3.  Error-prone DNA repair activity during somatic hypermutation in shark B lymphocytes.

Authors:  Catherine Zhu; Ellen Hsu
Journal:  J Immunol       Date:  2010-10-04       Impact factor: 5.422

4.  Sequence similarities of protein kinase substrates and inhibitors with immunoglobulins and model immunoglobulin homologue: cell adhesion molecule from the living fossil sponge Geodia cydonium. Mapping of coherent database similarities and implications for evolution of CDR1 and hypermutation.

Authors:  J Kubrycht; J Borecký; P Soucek; P Jezek
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

5.  Ancient phylogenetic beginnings of immunoglobulin hypermutation.

Authors:  Jaroslav Kubrycht; Karel Sigler; Michal Růzicka; Pavel Soucek; Jirí Borecký; Petr Jezek
Journal:  J Mol Evol       Date:  2006-10-06       Impact factor: 2.395

6.  Both DNA strands of antibody genes are hypermutation targets.

Authors:  C Milstein; M S Neuberger; R Staden
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

7.  Evidence of canonical somatic hypermutation in hairy cell leukemia.

Authors:  Evgeny Arons; Laura Roth; Jeffrey Sapolsky; Tara Suntum; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Blood       Date:  2011-03-02       Impact factor: 22.113

Review 8.  Somatic hypermutation and B-cell lymphoma.

Authors:  D Dunn-Walters; C Thiede; B Alpen; J Spencer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-01-29       Impact factor: 6.237

9.  Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells.

Authors:  Tatyana A Souza; B David Stollar; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

10.  Impact of phosphorylation and phosphorylation-null mutants on the activity and deamination specificity of activation-induced cytidine deaminase.

Authors:  Phuong Pham; Marcus B Smolka; Peter Calabrese; Alice Landolph; Ke Zhang; Huilin Zhou; Myron F Goodman
Journal:  J Biol Chem       Date:  2008-04-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.